^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GCR antagonist

    Related drugs:
    1m
    DAZALS: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov)
    P2, N=279, Active, not recruiting, Corcept Therapeutics | Trial completion date: May 2027 --> Nov 2027 | Trial primary completion date: Oct 2024 --> Sep 2026
    Trial completion date • Trial primary completion date
    1m
    Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Corcept Therapeutics
    New P1/2 trial
    |
    Opdivo (nivolumab)
    2ms
    Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Corcept Therapeutics
    New P2 trial
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel • relacorilant (CORT125134)
    3ms
    BELLA: Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (clinicaltrials.gov)
    P2, N=270, Recruiting, Corcept Therapeutics | N=90 --> 270
    Enrollment change
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • relacorilant (CORT125134)
    4ms
    Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, AVM Biotechnology Inc | Trial completion date: Mar 2025 --> Mar 2032 | Trial primary completion date: Dec 2024 --> Dec 2031
    Trial completion date • Trial primary completion date
    |
    dexamethasone sodium phosphate (AVM0703)
    4ms
    The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies (clinicaltrials.gov)
    P1/2, N=144, Recruiting, AVM Biotechnology Inc | Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    TP53 mutation • TP53 mutation + Chr del(17p)
    |
    dexamethasone sodium phosphate (AVM0703)
    7ms
    Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants (clinicaltrials.gov)
    P1, N=21, Completed, Corcept Therapeutics | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Aug 2024
    Trial completion • Trial completion date
    |
    itraconazole
    8ms
    The Selective Glucocorticoid Receptor Modulator Cort125329 Decreases Neuroinflammation and Gliosis and Enhances Myelination in the Wobbler Model of Amyotrophic Lateral Sclerosis. (PubMed, Mol Neurobiol)
    The beneficial effects of CORT125329 correlated with enhanced motor behavioral performance and trophic changes of the forelimbs. In conclusion, our results support further preclinical and clinical studies on GR modulators in sporadic amyotrophic lateral sclerosis.
    Journal • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • HMGB1 (High Mobility Group Box 1) • TLR4 (Toll Like Receptor 4) • BDNF (Brain Derived Neurotrophic Factor)
    9ms
    Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=178, Completed, Corcept Therapeutics | Active, not recruiting --> Completed
    Trial completion • Platinum resistant
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    albumin-bound paclitaxel • relacorilant (CORT125134)
    9ms
    Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, Corcept Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • relacorilant (CORT125134)
    9ms
    Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant (clinicaltrials.gov)
    P1, N=19, Completed, Corcept Therapeutics
    New P1 trial
    10ms
    Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Corcept Therapeutics
    New P2 trial
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • relacorilant (CORT125134)